
June 12 (Reuters) - Rein Therapeutics Inc RNTX.O:
REIN THERAPEUTICS : PAUSED ENROLLMENT AND PATIENT DOSING AT ITS CLINICAL TRIAL SITES IN UNITED STATES (U.S.) FOR ITS PHASE 2 RENEW TRIAL OF LTI-03
REIN THERAPEUTICS INC - RENEW TRIAL CONTINUES IN AUSTRALIA, UK, AND EUROPE - SEC FILING
REIN THERAPEUTICS INC - NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED FOR LTI-03 - SEC FILING
Source text: [ID:n0001193125-25-139950]